Journal
JOURNAL OF AFFECTIVE DISORDERS
Volume 163, Issue -, Pages 18-24Publisher
ELSEVIER
DOI: 10.1016/j.jad.2014.03.049
Keywords
Depression; Psychometrics; Research Domain Criteria
Categories
Funding
- Janssen-Cilag
- Agency for Healthcare Research and Quality (AHRQ)
- Corcept Therapeutics, Inc.
- Cyberonics, Inc.
- National Alliance for Research in Schizophrenia and Depression
- National Institute of Mental Health
- National Institute on Drug Abuse
- Novartis
- Pharmacia , Upjohn
- Predix Pharmaceuticals (Epix)
- Solvay Pharmaceuticals, Inc.
- Eli Lilly and Company
- Brain Resource Ltd.
- H. Lundbeck A/S
- Medavante, Inc.
- CINP
- Duke National University of Singapore
- Abbot Laboratories
- Alkermes, Inc.
- American Cyanamid
- Aspect Medical Systems
- AstraZeneca
- BioResearch
- BrainCells Inc.
- Bristol-Myers Squibb Foundation
- CeNeRx BioPharma
- Cephalon
- Clintara, LLC
- Covance
- Covidien
- EnVivo Pharmaceuticals, Inc.
- Euthymics Bioscience, Inc.
- Forest Laboratories
- Ganeden Biotech, Inc.
- GlaxoSmithKline
- Harvard Clinical Research Institute
- Hoffman-LaRoche
- Icon Clinical Research
- i3 Innovus/Ingenix
- Janssen Research and Development, LLC
- Jed Foundation
- Johnson & Johnson Services, Inc.
- Lichtwer Pharma GmbH
- Lorex Pharmaceuticals
- MedAvante
- National Alliance for Research on Schizophrenia & Depression (NARSAD)
- National Center for Complementary and Alternative Medicine (NCCAM)
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
- Neuralstem, Inc.
- Novartis AG
- Organon Pharmaceuticals
- PamLab, LLC.
- Pfizer Inc.
- Pharmacia-Upjohn
- Pharmaceutical Research Associates, Inc.
- Pharmavite(R) LLC
- PharmoRx Therapeutics
- Photothera
- Roche Pharmaceuticals
- RCT Logic, LLC
- Sanofi-Aventis US LLC
- Shire
- Synthelabo
- Wyeth-Ayerst Laboratories
Ask authors/readers for more resources
Background: Most depression rating scales are multidimensional and the resulting heterogeneity may impede identification of coherent biomarkers. The aim of this study was to compare the psychometric performance of the multidimensional 17 item Hamilton Depression Rating Scale (HAM-D-17) and the 30 item Inventory of Depressive Symptomatology (IDS-C-30) to that of their unidimensional six item melancholia subscales (HAM-D-6 and IDS-C-6). Methods: A total of 2242 subjects from level 1 (citalopram) of the Sequenced Treatment Alternatives to Relieve Depression (STAVE)) study were included in the analysis. Symptom change, response and remission rates were compared for HAM-D-6 versus HAM-D17 and for IDS-C-6 versus IDS-C-30. The changes in total scores on these scales were compared to the change in Quality of Life Enjoyment and Satisfaction Questionnaire (QLES-Q) score using correlation analysis. Results: The response to treatment was significantly greater according to the HAM-D-6 and IDS-C-6. Furthermore, the correlation of changes in depression-ratings with changes in QLES-Q scores were comparable for the subscales and full scales. Limitations: STAR*D was not designed to answer the research questions addressed in this analysis. Conclusions: Our findings indicate that the HAM-D-6 and IDS-C-6 melancholia scales capture a coherent construct in depression. The syndrome reflected in these scales is unidimensional, sensitive to specific pharmacological intervention, and therefore likely to have biological validity. We therefore believe that melancholia thus defined could be a valuable construct under the Research Domain Criteria (RDoC), which specifically aims at identifying the neurobiology underlying mental disorders and providing drugable targets. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available